The search for a predictive marker of sensitivity to anthracycline-based chemotherapy has proven challenging. Despite human epidermal growth factor receptor 2 (HER2) being a strong prognostic marker in breast cancer, the only therapies with which there is a recognized functional link to the HER2 oncogene are those directly targeting the molecule itself. Despite this, HER2 has been extensively assessed as a predictive marker in a variety of chemotherapy regimens including anthracyclines. Analysis of anthracycline response in patients with HER2 amplification has given conflicting results. This led to the suggestion that HER2 amplification was acting as a surrogate for the gene encoding topoisomerase IIa (TOP2A), a direct cellular target of anthracyclines. Despite an attractive functional link between TOP2A and anthracyclines, published studies have failed to show strong evidence of an interaction between TOP2A genetic aberrations and anthracycline response. A number of other biomarkers have also been assessed for their role in predicting anthracycline response, including TP53 (tumour protein 53) and BRCA1 (breast cancer 1, early onset), together with an increasing emergence of gene expression profiling to produce predictive signatures of response. Moreover, recent evidence has emerged from presentations suggesting new candidate markers of response that warrant further investigation: Chr17CEP duplication and tissue inhibitor of metalloproteases 1. This review will discuss research into HER2 and TOP2A as predictive markers of anthracycline response and will focus on current research into other possible candidate predictive markers.
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Anthracycline therapy
Anthracyclines are highly effective chemotherapeutic agents used in treating a broad range of malignancies (Minotti et al., 2004) . Their discovery in the 1960s and subsequent introduction into clinical practice led to significant improvements in the treatment of some cancers, most particularly lymphomas, breast cancer and sarcoma. More recently, they are increasingly used in the treatment of non-metastatic gastric and lower oesophageal cancers, breast, ovarian and lung cancers (Cortes-Funes and Coronado, 2007) . Although effective, these drugs have serious side effects, most notably cardiotoxicity, which is often under-reported because of it's late onset, and is becoming more of a clinical issue as treatments result in more long-term survivors of cancer, and as these drugs are increasingly offered to older patients (Eifel et al., 2001; Minotti et al., 2004) . Two of the most commonly used anthracyclines are epirubicin and doxorubicin. Epirubicin is the 4 0 -epimer of doxorubicin, with a different spatial orientation of the hydroxyl group at the C-4 0 position of doxorubicin (reviewed in Cersosimo and Hong, 1986) . This may contribute to the faster elimination rate and reduced toxicity of epirubicin, making it preferential, in some chemotherapy regimens, to doxorubicin.
Anthracyclines are thought to exert their actions by intercalation with DNA, generation of free radicals and crosslinking DNA to proteins (Minotti et al., 2004) . However, there remains insufficient data, even now, to link their mode of action to one or more of the observed actions of anthracycline exposure. Intercalation of anthracyclines into DNA is thought to reduce the synthesis of both DNA and RNA (Minotti et al., 2004) . Anthracyclines also catalyse the production of formaldehyde through induction of cellular oxidative stress. Formaldehyde then acts to mediate covalent bonding of the anthracyclines to DNA (Taatjes et al., 1999) , causing both production of DNA adducts and covalently linking some proteins (including the DNA gyrase topoisomerase IIa (TOP2A)) to DNA-stabilizing double-strand breaks (Taatjes et al., 1999; Spencer et al., 2003) . As cells enter mitosis, the presence of these stabilized double-strand breaks is thought to trigger either mitotic catastrophe or apoptosis. In vivo associations between increased DNA damage and expression of targets such as TOP2A have been cited to support the proposed predictive role of TOP2A for anthracycline benefit in early breast cancer. A further key by-product of the production of formaldehyde is an increased intracellular concentration of free radicals; these may facilitate the actions of anthracyclines discussed briefly above or may, independently of these actions, alter membrane function or inhibit key intracellular processes (Minotti et al., 2004) . With such broad-spectrum activities, it might at first seem surprising that so much effort has focussed on single gene alterations as predictive biomarkers of anthracycline response.
Genes that mediate cytoprotection from doxorubicin belong to multiple pathways, including DNA repair, RNA metabolism, chromatin remodelling, amino acid metabolism and heat shock response. Factors such as p53 and modulators of DNA repair and apoptosis have also been linked to anthracycline sensitivity (Fedier et al., 2003; Small et al., 2003; Di Leo et al., 2007) .
Anthracyclines in early breast cancer
Two key adjuvant breast cancer trials that highlight the benefit of anthracycline containing polychemotherapy are the National Cancer Institute of Canada Clinical Trials Group Mammary 5 (MA.5) study and the National Epirubicin Adjuvant Trial (NEAT/BR9601) (Levine et al., 1998 (Levine et al., , 2005 Poole et al., 2006) . Both the MA.5 study, comparing cyclophosphamide-epirubicinfluorouracil (CEF) with cyclophosphamide-methotrexatefluorouracil (CMF), and NEAT/BR9601, comparing epirubicin (E-CMF) with CMF, reported a gain in overall survival of 7% after 5 years (Levine et al., 1998; Poole et al., 2006) for patients treated with anthracyclines. Updated survival for the MA.5 study has shown a persistent gain in overall survival of 4% after 10 years (Levine et al., 2005) . Although these trials have shown a definite survival gain in patients treated with anthracyclines, the benefit, relative to the then conventional polychemotherapy (CMF), is modest and is accompanied by increased toxicity. In particular, outcomes in the control arms of these trials show that the majority of patients (470%) derive adequate disease control from non-anthracycline-containing therapies, challenging the need to treat 'all comers' with anthracyclines. This observation has driven attempts to identify those patient subgroups for whom anthracyclines provide benefit ( for example, see Hutchins et al., 2005) . Selection of patients most likely to benefit from anthracycline therapy would also allow better use of current cytotoxics and reduce the risk of patients receiving toxicity with little or no efficacy. In addition, identifying biomarkers that can accurately predict benefit from anthracyclines will highlight key resistance/susceptibility pathways that can then be exploited clinically to further increase efficacy.
Proliferation and tumour grade as biomarkers for chemotherapy/anthracycline therapy Early studies of anthracyclines suggested, as with many chemotherapy agents, that they are particularly effective against actively proliferating cells (Klijn et al., 1993) . Over a decade ago, Pegram et al. (1997) showed evidence suggesting that proliferation, but not human epidermal growth factor receptor 2 (HER2) amplification, was associated with anthracycline sensitivity (Klijn et al., 1993) . Evidence from published neoadjuvant studies suggests that tumours with high grade or high proliferative indices (measured by Ki67 and so on) respond preferentially to anthracyclines (VincentSalomon et al., 2004) . However, data from large adjuvant trials, such as NEAT, do not show a marked relationship between grade and benefit from the addition of anthracyclines to chemotherapy. More recent analyses (Bartlett et al., 2010 ) also fail to identify proliferation as a biomarker selecting patients for enhanced benefit from anthracycline-containing therapy. It would seem that simple measures of proliferation are unlikely to identify patient subgroups with enhanced benefit from adjuvant anthracycline therapy, although they may still indicate tumours with more general chemosensitivity.
HER2 and proliferation: mechanism or opportunism?
Given the suggested link between proliferation and polychemotherapy response in general, and anthracyclines in particular, the association between HER2 and proliferation explains the early interest in HER2 as a predictive biomarker of anthracycline response. HER2 represents one of the most extensively studied biomarkers in breast cancer. Overexpression and amplification of HER2 is observed in approximately 20-25% of early breast cancers eligible for chemotherapy (Slamon et al., 1989; Bartlett et al., 2001) and is commonly associated with increased tumour aggressiveness, increased risk of recurrence and reduced survival. HER2 amplification/ overexpression, together with other HER family members, have been linked to increased proliferation in vivo (Borg et al., 1991; Tovey et al., 2004) .
HER2 as a predictive biomarker for selection of dose-dense or high-dose chemotherapy HER2 was first associated with response to anthracyclines in retrospective studies of trials assessing the benefit of anthracycline dose escalation or dose acceleration in which all patients received anthracyclines with differing doses/schedules. The earliest and largest of these studies, comprising almost 2000 patients, from the CALGB (Cancer and Leukemia Group B) 8541 chemotherapy trial (Muss et al., 1994) suggested that women with tumours showing high HER2 expression (defined as tumours with X50% HER2-overexpressing cells) experienced an increased benefit with increasing dose of adjuvant anthracyclines in terms of relapse-free survival when compared with women with low HER2-expressing tumours. Similarly, in the GONO-MIG-1 (Del Mastro et al., 2005) study, the HER2-positive subpopulation showed increased event-free survival and overall survival when treated with dose-dense anthracyclines. Indeed, in studies of dose-dense chemotherapy, with large patient numbers, the interaction between HER2 overexpression and benefit from dose-dense scheduling of anthracyclines seems relatively robust, although none of the later trials evaluated similar size populations to those studied in the CALGB trial and no prospective validation or centralized meta-analysis has been performed. However, as none of these trials compared anthracyclines with a non-anthracycline control arm, it is difficult to directly extrapolate conclusions relating to HER2 as a predictive marker for selecting patients specifically for higher-dose anthracyclines as opposed to higher overall doses of chemotherapy. Such trials, when considering relationships between biomarkers and outcome, provide weaker evidence in favour of predictability of benefit from a specific agent (or class of agents) than studies that compare regimens with different chemotherapeutic agents. It can be argued that it is logical to conclude from these studies that HER2 may indeed identify cases requiring more aggressive treatment (with dose escalation), but there is only weak evidence that this effect is solely related to the anthracycline aspect of the treatment regimen.
Recent models of tumour response to cyclical exposure to chemotherapy suggest that the benefit of multiple cycles of chemotherapy is partially offset by the potential for tumour regrowth in the resting period between cycles (Norton, 2008) . This model would suggest that tumours with increased proliferation rates would show increased risk of relapse after conventional chemotherapy and benefit preferentially from acceleration. Widespread evidence that proliferation is a key marker of chemotherapy 'failure' supports this hypothesis (Tordai et al., 2008; Schmidt et al., 2009) . This hypothesis would suggest that the link between HER2 amplification/overexpression and increased proliferation drives proportionally greater growth of HER2-positive tumour cells between treatment cycles than that of HER2-negative cells. Therefore, suggesting more frequent or 'dose-dense' scheduling of treatment may be advantageous for the treatment of HER2-positive disease, regardless of the treatment regimen. This is a hypothesis that remains to be fully validated in the context of modern trials of accelerated chemotherapy.
HER2 as a marker of anthracycline sensitivity
After publication of results (reviewed above) from early anthracycline trials assessing HER2 in the context of dose escalation, further studies were performed to test the hypothesis that HER2 acts as a predictive marker for the identification of tumour response to anthracycline rather than CMF-based therapy. This concept was subsequently assessed in a number of trials with varying, although modest, sample sizes comparing anthracycline therapy to a non-anthracycline control arm with inconclusive results (Paik et al., 1998 (Paik et al., , 2000 Di Leo et al., 2001 Pritchard et al., 2008) .
To date, in studies encompassing 43000 patients, the MA.5 trial is the only trial to show statistically significant evidence that in patients with HER2-positive cancers there was greater benefit of anthracycline therapy when compared with non-anthracycline therapy (with a significant 'treatment by marker interaction') (Pritchard et al., 2006) . Although many previous trials show a trend towards improved outcomes in the HER2-positive population treated with anthracyclines (Paik et al., 1998 (Paik et al., , 2000 Di Leo et al., 2001 , these analyses did not show a statistically robust interaction between HER2 and sensitivity to anthracyclines. Few of these studies were individually powered to detect such an interaction, and hence many have interpreted this discrepancy as a factor of small sample sizes, suggesting that the analysis of larger, statistically powered studies were required. In contrast, the earliest and the largest study to date (Paik et al., 1998) failed to show a clear treatment by marker interaction for HER2 in the context of anthracyclines. Furthermore, a separate, prospectively powered, analysis of the UK NEAT/ BR9601 (National Epirubicin Adjuvant Trial/BR9601 trial) (Bartlett et al., 2010) showed no predictive effect of HER2, and a meta-analysis of the Belgian (Di Leo), Canadian (MA.5), United Kingdom (NEAT), Scottish (BR9601) and Danish (DBCG 89D) phase III anthracycline trials showed only borderline significant effects for HER2 in selecting patients who benefit from treatment with anthracyclines with respect to recurrence-free survival and no significant effect on overall survival (Di Leo et al., 2009; Bartlett et al., 2010) . Both analyses were independently performed and both were sufficiently powered to test the hypothesis that there was significantly greater benefit from the addition of anthracyclines in patients whose tumours overexpressed HER2. However, the NEAT/BR9601 trial did not substantiate the effect that was suggested by the studies of dose escalation or the modest effect observed in the MA.5 trial. Results from the recent meta-analysis also suggest at best a modest effect of HER2 as a potential predictive marker and show that a significant proportion of patients with HER2-negative tumours also benefit from anthracyclines (Di Leo et al., 2009) . This study therefore also fails to fully substantiate a role of HER2 as a predictive biomarker to select patients likely to benefit from anthracycline therapy.
Caution must be applied in interpreting different trial designs (the Belgian study included anthracycline dose escalation) and when choosing methods of HER2 assessment. Furthermore, two studies on the interaction between HER2 and anthracycline benefit have shown internal inconsistencies between different detection methods (Di Leo et al., 2004; Pritchard et al., 2006) . Di Leo et al. (2001) tested a variety of commercially available HER2 antibodies highlighting discordance between methods; depending on the antibody used, the percentage of tumours with HER2 overexpression ranged from 8 to 18%, which clearly affects the analysis performed. Assessment using one immunohistochemistry method showed a nonsignificant trend towards increased survival in HER2-positive patients, whereas another did not. Similarly, in the analysis of the MA.5 trial, a variety of methods such as immunohistochem-istry, fluorescence in situ hybridization and PCR were used and again, despite substantial agreement between detection methods, marked differences in the hazard ratios for the treatment interaction were apparent (Pritchard et al., 2006) , and only for HER2 fluorescence in situ hybridization was it statistically significant (in the absence of correction for multiple testing).
Individually, the earlier studies neither confirmed nor refuted the role of HER2 as a marker of anthracycline response. The main reasons for inconclusive results stem largely from studies that are not sufficiently powered to answer the question robustly. This, together with methodological inconsistencies, compromised the results of these studies. However, larger studies, including the recent meta-analysis, also fail to show any consistent predictive value of HER2 amplification or overexpression with respect to anthracyclines (Di Leo et al., 2009; Bartlett et al., 2009a) , in direct contrast to the early studies of dose escalation. It would seem that although HER2 and proliferation may select for patients more likely to respond to dose-dense therapy, there is now clear evidence that both HER2-positive and HER2-negative tumours can respond to anthracycline treatment (Di Leo et al., 2009; Bartlett et al., 2009a Bartlett et al., , 2010 . Therefore, on the basis of current evidence it would seem inappropriate to withhold anthracyclines from HER2-negative patients.
TOP2A and markers of DNA damage DNA damage and anthracyclines After early inconclusive results for studies of HER2 as a biomarker, research focussed on the possibly that HER2 was acting as a surrogate marker for another gene. The discovery that TOP2A was in close proximity of HER2 on chromosome 17 gave rise to an increased interest in TOP2A genetic aberrations and its overexpression with respect to anthracycline response. As anthracyclines directly target TOP2A among a range of other proteins, this was a potentially more functionally relevant approach. Data linking both TOP2A amplification and deletion to amplification of the HER2 gene (Jarvinen et al., 1999; Jarvinen and Liu, 2003) gave credence to this hypothesis.
Several studies have assessed the interaction between TOP2A amplification or deletion and response to anthracyclines (Di Leo et al., 2001; Knoop et al., 2005; Slamon et al., 2005; O'Malley et al., 2006; Tanner et al., 2006; Nielsen et al., 2008) . Similar to analysis of HER2, TOP2A has been assessed as a predictive marker of anthracycline response in both dose-escalation studies and anthracycline versus non-anthracycline trials. One of the first studies to assess TOP2A aberrations was a Belgian study by Di Leo et al. (2001) comparing two doses of anthracycline-based therapy (epirubicin and cyclophosphamide) with CMF. Results suggested an advantage of both doses of epirubicin and cyclophosphamide over CMF in TOP2A-amplified patients but no significant treatment by marker interactions were observed. This was a relatively small study group of 430 patients, with 73 patients amplified for HER2 and 23 amplified for both HER2 and TOP2A. Therefore, analysis of TOP2A aberrations in the presence of HER2 amplifications, in a trial comparing three different therapy regimens, resulted in the analysis being statistically underpowered. The SBG (Scandinavian Breast Group) trial 9401 analysed TOP2A in the context of HER2-amplified tumours (Tanner et al., 2006) . SBG 9401 compared varying doses of tailored dose-escalating FEC with standard FEC followed by CTCb (cylophosphamide, thiotepa, and carboplatin). Results showed a significant treatment by marker interaction between co-amplification and high doses of FEC (hazard ratio 0.300, 95% confidence interval (CI) 0.11-0.83, P ¼ 0.020). However, with the lack of a non-anthracycline control arm in the SBG 9401 trial, this response is only indicative of greater benefit from higher doses of anthracycline-based chemotherapy, and no firm conclusion can be made about a specific interaction with anthracyclines. One of the first trials to show a significant interaction between TOP2A and anthracycline response was the DBCG 89-D trial (Knoop et al., 2005; Nielsen et al., 2008) . This study analysed TOP2A aberrations in 1224 tumours with or without HER2 amplification. Similar to results from the Belgian trial, the analysis showed TOP2A amplifications, but not deletions, to be predictive of outcome on anthracycline-based therapy. However, subsequent studies, including that in the NEAT/BR9601 trial, failed to confirm this finding (Bartlett et al., 2009a) . Taken together, studies analysing the interaction between HER2/TOP2A genetic aberrations or TOP2A genetic aberrations have failed to either confirm or refute their role as predictive markers of anthracycline response (Knoop et al., 2005; Di Leo et al., 2009; O'Malley et al., 2009; Bartlett et al., 2009a) . Similar to results for HER2, the recent meta-analysis of four phase III anthracycline trials suggests that TOP2A amplified, deleted and nonamplified cases may all gain greater benefit from anthracycline treatment than CMF (Di Leo et al., 2009; Bartlett et al., 2009a) .
Early in vitro studies of TOP2A gene aberrations suggested TOP2A amplification and deletion to be associated with increased sensitivity and resistance to TOP2A inhibitors, respectively (Jarvinen et al., 2000b) . TOP2A may be linked to reduced protein expression and this reduction in target levels could explain the relative resistance of TOP2A-deleted cells to anthracyclines (Jarvinen et al., 2000a; Di Leo and Isola, 2003) . Subsequent studies in patient samples have largely failed to confirm this finding, with a number of studies paradoxically reporting increased sensitivity in both TOP2A amplified and deleted tumours (Knoop et al., 2005; Di Leo et al., 2009; O'Malley et al., 2009) . If correct, this challenges the mechanistic assumptions underlying current research that increased gene dosage of TOP2A (observed in amplified cases) is linked to increased response to anthracyclines.
In addition, a recent study has challenged the incidence of HER2 and TOP2A co-amplification reported by conventional fluorescence in situ hybridization analysis (McArthur et al., 2009) . Analysis of HER2 and TOP2A using representational oligonucleotide microarray analysis suggests that TOP2A amplification is a rare event in HER2-amplified tumours. Other studies have recently reported that TOP2A amplification is not, as previously suggested, strictly related to HER2 amplification (Bhargava et al., 2005; Todorovic-Rakovic et al., 2009 ). This contrasts with results from multiple fluorescence in situ hybridization-based analyses (see above). Further exploration of the true amplification rate for TOP2A in early breast cancer is warranted. In addition, the results of the Belgian TOP trial may provide additional insights, as they treated a series of patients with large operable and locally advanced breast cancers with epirubicin monotherapy preoperatively to test the hypothesis that TOP2A could be a predictor of anthracycline sensitivity, although the trial was stopped before the required patient numbers were reached and therefore may be underpowered to address key questions.
In summary, evidence of a clear association between TOP2A and anthracycline response is not yet forthcoming. Researchers may need to analyse further afield to identify pathways within breast cancer cells that are associated with response to anthracyclines, and/or other links to chromosome 17, on which both the TOP2A and HER2 genes are located.
Novel markers and DNA repair
With the suggestion that both HER2 and TOP2A could be acting as surrogate markers, the question that remains is whether the true marker is functionally or genetically linked to its proposed surrogates. Data are emerging that suggest that the true marker of anthracycline sensitivity may have both a functional and a genetic link to HER2 and TOP2A. Recent evidence has suggested polysomy of chromosome 17 (more recently defined as duplication of the centromeric region (CEP)) as a predictive marker of anthracycline sensitivity (Bartlett et al., 2009a (Bartlett et al., , 2010 . Chr17CEP duplication may imply a possible disruption of cell cycle dynamics, DNA repair mechanisms and proliferation, thereby providing a functional link to both HER2 and TOP2A. The effect of Chr17CEP duplication and the resultant increased gene dosage of numerous chromosome 17 genes pivotal to breast cancer may provide an indirect genetic link to the true marker of sensitivity.
Chromosome 17 centromere duplication
Evidence of chromosome 17 as a potential predictive marker of outcome was presented at the SABCS (San Antonio Breast Cancer Symposium) in 2007 (Reinholz et al., 2007) . Reinholz et al. (2007) tested the hypothesis that chromosome 17 may be predictive of outcome on trastuzumab in 1888 patients recruited into the HER2 þ N9831 intergroup adjuvant trastuzumab phase III clinical trial. Despite chromosome 17 not being predictive of trastuzumab response, results suggested that patients receiving standard chemotherapy in the absence of trastuzumab, and who had polysomy of chromosome 17, benefited more than those with normal levels of chromosome 17.
This was recently confirmed in an analysis of BR9601, NEAT and MA.5 (Bartlett et al., 2009a (Bartlett et al., , 2009b (Bartlett et al., , 2010 . Analysis of Chr17CEP duplication in BR9601, NEAT and MA.5 suggests chromosome 17 to be an independent predictive marker of anthracycline sensitivity. Therefore, Chr17CEP duplication provides the first unifying hypothesis of anthracycline response within three trials for which the HER2 data are opposing (Di Leo et al., 2004 Leo et al., , 2009 Knoop et al., 2005; Pritchard et al., 2006; Reinholz et al., 2007; Bartlett et al., 2008 Bartlett et al., , 2009a Bartlett et al., , b, 2010 . Analysis of Chr17CEP in tumours recruited into the Belgian trial is near completion, which would allow a meta-analysis of chromosome 17 in 2975 patients. The combined analysis of BR9601, NEAT, MA.5 and the Belgian trial is keenly awaited and has the potential to determine whether Chr17CEP is a common identifier of patients who may derive benefit from anthracyclines in early breast cancer. If so, novel candidate genes related to Chr17CEP duplication may supply a mechanistic explanation of anthracycline benefit. Further validation in other tumour types, including ovarian, gastric and lymphoma, may provide additional supporting evidence.
Mechanisms, causes and consequences of polysomy
Duplication of Chr17CEP does not, however, immediately identify a functional link to a specific gene pathway. The CEP probe targets a non-coding pericentromeric a-satellite repeat on chromosome 17 that can both enumerate chromosome copy number (hence CEP) and identify duplication of this region within the chromosome (without chromosome duplication). What then are the potential mechanisms linked to anthracycline treatment that are identified by duplication of this genomic region? We have identified three key events for future investigation: the effect of increased gene copy numbers on chromosome 17, the incidence of global genomic/chromosomal instability and disruption of the cell cycle pathways responsible for maintaining normal cell division.
Chromosome 17
Chromosome 17 is the second most gene-dense chromosome in the human genome, containing many genes central to breast cancer and DNA repair including HER2, TOP2A, BRCA1 (breast cancer 1, early onset) and TP53 (tumour protein 53) (Fraser et al., 2003; McClendon and Osheroff, 2007; Pritchard et al., 2006; Olivier et al., 2008; Greenberg, 2009) . Furthermore, the 17q12-q21 chromosomal region that incorporates HER2 is a gene-rich region of genetic instability that is pivotal to tumour progression and poor prognosis in breast cancer. Owing to the high level of coordinated genetic aberrations within this region, it may prove challenging to pinpoint the gene(s) responsible for driving the response to chemotherapeutic agents. HER2 is the most recognized and studied gene within the region, with amplification of HER2 being associated with amplifications and deletions of neighbouring genes including GRB7, RARA, THRA1, CDC6 and TOP2A (Arriola et al., 2008) . It has recently been shown that the patterns of coordinated genetic aberrations are inconsistent between HER2-amplified tumours (Arriola et al., 2008) . However, Arriola et al. (2008) only considered 19 HER2-amplified tumours and did not consider genetic alterations in HER2 non-amplified tumours. Previous to the work by Arriola et al. (2008) , Orsetti et al. (2004) assessed genomic gains and losses on chromosome 17 in 22 breast cancers irrespective of HER2 amplification status. Genomic gains and losses varied markedly between tumours with only 18% of tumours showing no genomic alterations. Strikingly, the majority of tumours showed regions of gains (and small regions of losses) within the 17q22-q24 region, with only seven tumours showing no alteration within this region. The 17q22-q24 region was first identified as a region of genetic instability in breast cancer (Kallioniemi et al., 1994) and alterations are a frequent event in aneuploid breast tumours (Ried et al., 1995) . However, increased copy numbers at 17q23 are also a frequent event in a variety of tumour types, including brain, lung, ovarian and bladder (Andersen et al., 2002) .
Chromosome 17 alone or something more global?
The detection of aneuploidy is relatively simple; however, the mechanisms involved in the development of aneuploidy are more complex and potentially diverse. Chromosomal instability (CIN) is a frequent event in human cancer and is defined as an increased rate of chromosome aberrations. Cell cycle regulation is important in ensuring daughter cells receive one copy of chromosomes from parent cells. As cells progress through the cell cycle, they are regulated by cell cycle checkpoints that prevent progression if certain requirements are not met. The spindle assembly checkpoint (SAC) is essential for ensuring cells do not enter anaphase until all chromosomes are aligned along the mitotic plate under bipolar tension. Defects in proteins associated with the SAC enables cells to prematurely enter anaphase and can result in chromosome missegregation, CIN and aneuploidy, a functional consequence of CIN. Therefore, it is plausible to suggest that defects in the SAC, or CIN, may be responsible for the association between chr17CEP and anthracycline sensitivity. Studies have shown that a functional SAC is required for mitotic cell death induced by drugs targeting topoisomerase, including doxorubicin. Cells with a compromised SAC escape from doxorubicininduced apoptosis.
A gene signature for chromosomal instability was recently published in Nature Genetics that claims to be predictive of poor clinical outcome (Carter et al., 2006) . Carter et al. (2006) identified a signature (CIN25) involving 25 genes that frequently correlate with aneusomy and can predict survival in numerous independent cohorts of various cancer types. The CIN25 signature was derived from the top 25 ranked genes of a CIN70 signature that showed similar results to the smaller gene set. The CIN70 signature contained genes such as TPX2, TOP2A, MAD2L1, CCNB1, CCNB2, CDC20, PTTG1, ZWINT1, STK6 and CDC6; the genes known to be involved in processes such as DNA replication, chromosome segregation and cell cycle checkpoint control. If this gene signature can accurately measure the level of CIN within tumours, it offers an attractive method of characterizing tumours.
The genes that have been included in CIN25 highlight the importance of assessing genes that are functionally involved in the cell cycle to pinpoint key genes that may be important in response to anthracyclines. A defect in genes associated with the mitotic spindle checkpoint is one of the mechanisms known to give rise to abnormal cell division and aneuploidy. Mutations that disrupt the retinoblastoma pathways are a frequent event in tumours (reviewed in Nevins, 2001 ). Disruption of the retinoblastoma pathway causes a deregulation of the E2F family of transcription factors, which are important regulators of the cell cycle, and subsequently promotes genomic instability (Hernando et al., 2004) . MAD2 (mitotic arrest deficient protein 2) and BubR1 are mitotic checkpoint proteins that act synergistically to inhibit activation of the anaphase-promoting complex/ cyclosome. This subsequently leads to an accumulation of securin (PTTG1) and cyclin B, thereby prolonging progression of mitosis to anaphase. Recent research has shown expression of MAD2, a direct target of the E2F family, to be associated with increased sensitivity to DNA-damaging agents (Cheung et al., 2005; Du et al., 2006; Fung et al., 2006) .
Other potential or emerging markers
Tissue inhibitor of metalloproteases 1 (TIMP-1) is an emerging tumour biomarker that has a complex role in cancer (reviewed in Jiang et al., 2002; Wurtz et al., 2008) . It has been shown to be elevated in a number of human cancers, including breast, and has been associated with a poor clinical outcome (Ree et al., 1997; Holten-Andersen et al., 2000; Schrohl et al., 2004) . HER2 expression has been associated with the expression of metalloproteinases and contributes to an invasive phenotype, which may be linked to TIMP-1 expression (Pellikainen et al., 2004) . Recent studies have shown that elevated levels of TIMP-1 in plasma or serum may give rise to endocrine resistance in metastatic breast cancer (Lipton et al., 2008) . In vitro and in vivo studies have also suggested that a high level of TIMP-1 protects tumour cells against chemotherapy-induced apoptosis (Davidsen et al., 2006; Schrohl et al., 2006) . Data presented by Ejlertsen et al. (2010) at SABCS (2008) suggested that TIMP-1 and TOP2A collectively predict response to anthracycline therapy. Patients from the DBCG 89-D were subdivided into a responsive group (TOP2A abnormal or TIMP-1 negative) and a nonresponsive group (TOP2A normal and TIMP-1 positive). Patients in the 'responsive' group who were treated with an anthracycline regimen (CEF) had hazard ratios of 0.48 (95% CI 0.34-0.69) for relapse and 0.54 (95% CI 0.38-0.77) for death when compared with patients receiving non-anthracycline regimen CMF. Patients in the 'nonresponsive' group had hazard ratios of 1.18 (95% CI 0.87-1.60) for relapse and 1.07 (95% CI 0.78-1.47) for death. Although these are interesting data, there is no functional link between TOP2A and TIMP-1; the rationale behind combining these markers seems unclear. However, further validation of the TOP2A and TIMP-1 profile is warranted to determine whether the combination of these markers is more beneficial than the individual markers alone.
To date, research has centred on cancer cell-specific responses to therapy. Recent evidence suggests that stromal elements and immune elements within the tumour may mediate response to chemotherapy (Teschendorff et al., 2007; Finak et al., 2008; Ghiringhelli et al., 2009; Denkert et al., 2010) . No evidence has yet emerged that these elements of tumour biology are specifically related to response to anthracyclines but further evidence may emerge in the future.
As discussed above, chromosome 17 harbours numerous genes central to breast cancer, and these include tumour suppressors TP53 and BRCA1. TP53 is involved in cellular processes such as DNA repair and apoptosis. Owing to the differing drug regimens and tumour subtypes tested, the analysis of TP53 mutations (and p53 protein expression) and anthracycline response has given conflicting results (Bidard et al., 2008) . Although some reports suggest that TP53 mutations confer resistance to anthracyclines (Aas et al., 1996; Rahko et al., 2003) , others have shown mutations to increase sensitivity (Bertheau et al., 2002 (Bertheau et al., , 2009 . Similarly, BRCA1 has multiple roles in breast cancer including DNA damage repair, transcriptional regulation, and regulation of cell cycle checkpoints. The majority of studies have shown that absence of BRCA1 leads to hypersensitivity to DNA-damaging agents. Patients with BRCA1 mutations have shown a significant gain from treatment with anthracycline therapy (Fedier et al., 2003; John, 2003; McCullough et al., 2007; Kim and Chen, 2008; Murphy and Moynahan, 2010) .
Another approach is the use of gene expression profiling to predict response to anthracyclines (Biganzoli et al., 2007; Bonnefoi et al., 2007) . The use of gene expression profiling enables the simultaneous analysis of multiple genes involved in various pathways pivotal to breast cancer. Although it has been proven that single genes can be independent predictors of outcome on varying chemotherapy regimens, the effect of multiple genes should, in theory, provide a signature of response more potent that a single gene alone. Despite several studies claiming to have accurately produced a predictive profile, it seems that they require further validation before being used in the clinical setting.
Conclusion
Numerous studies have tried to elucidate the role of potential biomarkers of anthracycline sensitivity. Despite some success, results for the majority of markers tested remain inconclusive. The main reasons for inconsistent results seem to be because of both methodological problems and statistical underpowering. Another reason may be that the markers that are being recurrently tested are not the true markers of anthracycline response. Therefore, researchers must remain open to new emerging biomarkers and future studies must be planned more carefully to enable adequate statistical power for the biomarker in question. Emerging markers such as Chr17CEP duplication and TIMP-1 provide new areas of research for which further validation is required. Perhaps more importantly, such novel markers may also provide the potential for critical insights into the mechanisms underpinning response/ resistance to anthracyclines. Finding the true marker of anthracycline response is beginning to look less like a dream, and more like a reality. With the realization of this goal comes the opportunity to identify novel mechanisms of drug resistance and new targets for therapeutic intervention in early breast cancer.
